Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Acquires New Position in Eli Lilly and Company $LLY

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 51,591 shares of the company’s stock, valued at approximately $40,217,000. Eli Lilly and Company makes up about 4.7% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s holdings, making the stock its 7th largest holding.

Other large investors also recently modified their holdings of the company. Precedent Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after buying an additional 39 shares during the period. Capital Advisors Inc. OK increased its stake in Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after purchasing an additional 429 shares during the period. Family CFO Inc purchased a new position in Eli Lilly and Company in the 2nd quarter worth approximately $54,000. Duquesne Family Office LLC increased its stake in Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after purchasing an additional 32,640 shares during the period. Finally, Corient IA LLC purchased a new position in Eli Lilly and Company in the 1st quarter worth approximately $570,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In related news, CEO David A. Ricks purchased 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock valued at $2,894,841 over the last three months. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Down 2.6%

NYSE:LLY opened at $833.08 on Friday. The company’s 50 day moving average price is $742.42 and its 200-day moving average price is $765.94. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The stock has a market cap of $788.47 billion, a price-to-earnings ratio of 54.45, a PEG ratio of 1.16 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the business posted $3.92 EPS. The company’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the topic of several analyst reports. Cantor Fitzgerald set a $925.00 target price on shares of Eli Lilly and Company and gave the stock an “overweight” rating in a research note on Thursday. Wall Street Zen cut shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Leerink Partners restated a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. HSBC boosted their price target on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Finally, DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $948.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.